Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Top 5 Country Music Streams via PlayMPE.
http://jjolleymusic.wordpress.com/2012/11/17/yesterdays-most-active-releases-in-the-country-format-top-5-play-mpe-downloads-and-streams/
Andrea Bocelli Album promo released via PlayMPE.
'... Bocelli has always enthusiastically shared his classical calling. The album, via Play mpe, will be landing in your inbox imminently.'
http://www.femalefirst.co.uk/competitions/Andrea+Bocelli-264614.html
Article published November 5, 2012
Maybe Grapefruit lovers are realizing the need for GastroPlus software today.
Grapefruit Juice does not mix with some drugs.
http://health.yahoo.net/experts/dayinhealth/grapefruit-and-medications-may-be-deadly-mix
The need for SLP's GastroPlus software is expanding. It can compute the toxicity potential between drugs and food and drugs.
I find it stunning that your are invested in DSNY. Everything you write leads me to belief something else.
Instead of questioning the positive statements on this board, you could actually contribute to the research here.
All I have seen from you are statement that shorts usually make.
If you need examples, please read your own posts.
zstockings. I left out the verb in my previous message.
My English was poor, sorry. I could not change it when I saw the problem.
timorr. It is never good to announce the obvious.
As an investor, you only remind yourself and everyone else about the short-term pain.
It does not matter if this stock goes to 5 cents in the short term. It will be up again soon enough when the product promotion starts to hit the media.
I wanted to all 30k, but I only bought a few shares today.
You may get another chance. Someone shares bought at 77 cents today.
The fiscal cliff issues won't effect Destiny's business as much as other companies.
The revenues are derived from worldwide music distribution.
Even if music sales go down, the music promotion effort goes up. So Destiny promotional revenues go up.
What makes your ID suspicious here is that I can only find one other website that you posted to using the brooklyn13 ID link on ihub.
iHub allows uses to view other users message board activity. However, you do not seem to be invested here, yet you seem very opinionated about the value of this stock.
Now you say that you lost money on another stock, but I can't tell which other stock you care about. At one time, you posted on IMMY and I think you are using the ragingbull ID 'Itnfn', but that is only a guess.
So your reason for expressing yourself on this DSNY board is a mystery.
DSNY is not a pump and dump stock.
The pump and dump website measures the occurrence of STOCK SYMBOL references in messages on message boards other than the dedicated message board.
To rank on the P&D site, the stock has to have active posters who are writing messages about DSNY on 50 or 100 message boards. They are called Touts on that website. I do not know the exact rule, but the posts have to be multiple different boards on the same day over a number of days.
That is not the case here. On occasion, there are discussions about other stocks here, but it is not routine.
DSNY is also a profitable company with earnings growth and new products on the way. DSNY may never meet the P&D website criteria due to the earnings and profits.
I do not mind negative posters if the poster has facts to back up their statements.
There are no official board moderators on DSNY. There has not been a problem here so far.
I know there are problems with other stocks. TAGG was mentioned here. I count that stock as a bad pump and dump. There are many other companies who have dubious business plans and meager chances for success.
DSNY is not in that group. DSNY is profitable and growing earnings.
I am puzzled that you raise this issue on this board. Every stock is manipulated in some respect or another. It is buyer beware - even when you buy NFLX or AAPL. The shorts battle with the longs over the short term movement of every stock.
What 'fraudulent and manipulative information'?
Most of the messages on DSNY board are factual except for some of the hearsay from a few posters.
Your statements are mostly speculative to the downside.
You may not get your fill at 77 cents.
There is 77.5 cents if you want it. The big seller at 77.5 cents is gone.
Correction - someone bought the big block of 30K shares.
No. It is a quite period before Thursday.
Earning Report on Thursday, CC on Friday.
http://finance.yahoo.com/news/conference-call-advisory-destiny-media-055200029.html
My ID says that I make money investing in DSNY.
Please find another stock that you believe in. The facts spilled here on this message board do not seem brighten your day.
I am invested in DSNY now because I would rather be a little early than a little late or very late.
Good businesses make plans that take time to implement over weeks, months, quarters, even a year.
Next week, next quarter, next year are valid terms if you think like a business executive.
Your ihub ID says a lot about you. Instant gratification.
Please move on to another stock where you will be happy.
The music market has changed in a year.
This week's results and next quarter will be revealing to that change.
The music industry is shifting to all digital formats for most of their music sales in 2013.
Universal just acquired EMI - although that acquisition occurred after the quarter ended.
The PlayMPE v5 has been underdevelopment for a couple of years. The improvements may spur more users.
The PlayMPE software is now in 5 languages. DSNY has mentioned up to 27 languages to accommodate global music markets. The growth schedule is currently targeting German, French, and Japanese music markets.
I don't need to see huge numbers, but a comparative better quarter to last year would be great to see. Q4 is typically their worst quarter for sales - so I can't expect huge numbers.
Q1 released in January will be their biggest sales of the year for PlayMPE revenues. Those numbers will a better comparative given the Universal acquisition and the Christmas season.
SLP is changing the Drug Development process.
There are only two main players - SLP and Certera (with its SimCyp and WinNonLin solutions).
SLP expanded its training courses to use them as a marketing method. I recently read the SimCYP has scheduled an introductory course for its software in February 2013. Imitation by competitors is a great sign of success.
I think the next New Chemical Entity project could be one of the following: HIV, TB, West Nile Virus, or a Diabetes solution. HIV and TB are global problems. West Nile Virus and Diabetes are growing problems in the biggest market in the world.
Imagine what a solution to Diabetes could generate in revenues.
SLP seems to walk a tightrope on any drug development projects that might compete with their customers. I think our CEO should go after the biggest treasure to scare the crap out of the pharmas who hesitate to buy and use the software that can actually develop the best drug solutions at the lowest cost.
The Beta version might be released and announced.
I can't see how the final version will be released since they have not announced a beta version yet.
The annual report sales will be very telling on the success of PlayMPE v5.
You might find some Cyber Monday deals.
It is the holiday season after all. The jolly Christmas elves like to grant holiday wishes.
My sleuthing on the Malaria Drug opportunity is still in process.
This opportunity is much bigger than I knew about. The cost of the recommended Malaria Drug treatments run from $2 to $9 depending on the type of malaria and drug combinations required to treat drug resistant strains. The treatment is typically a 48 hour, 72 hour, or 96 hour medication schedule. The World Health Organization subsidizes some of these costs to allow poor countries to use the right drugs rather than less effective drug options or counterfeit ones.
If SLP develops a better drug solution than the current A.C.T. drug cocktail, then our royalties could be rather large. The malaria epidemic is huge. Although many of the patients are in poor countries, the problem is a global health epidemic. Countries will fund SLP's solution - if it saves them money over the current system.
New Article on solving Heart Disease and HIV/AIDS with multiple medications - a solution that requires complex Drug-Drug-Interactive research and modeling.
http://rd.springer.com/article/10.1007/s13556-012-0002-2/fulltext.html
September 2012 Presentation on PBPK.
http://www.nedmdg.org/docs/2012/2012FallDinner/Schuck_PBPK-BasedPredictions.pdf
This may be interesting to new investors. It is the most recent presentation that I have found online. Published by EISAI.
Drug Formulation consultant scientist compares GastroPlus with WinNonLin as two competing software applications for PBPK.
He discusses GastroPlus, but fails to describe WinNonLin in detail.
http://www.pharmadirections.com/_blog/Formulation_Development_Blog/post/PK_Modeling_Approaches_for_Formulation_Development/
Pharmogo is promoting GastroPlus in China.
They hosted two training courses last spring.
I found one of the promotional website pages. The following sentence is a translated sentence using Google translator.
'To ensure the effectiveness of training, up to 50 persons per class, after notice of the first round, has been overwhelming positive response from the majority of Chinese users and application.'
It appears that each class can accommodate 50 people - at least in China. Pharmogo seems to be introducing Simulation software into the Chinese market - so SLP should dominate the Chinese market unless they choose to use low quality software to make their low quality drugs.
Training Prices:
'Enterprise user 5,600 Yuan; Academic user 5,000 yuan;'
5,000 yuan = $802 as of today.
Actually, this is BLACK FRIDAY today.
While all the average shoppers are out trying to buy a cheap TV, the smart shoppers are here buying cheap shares of great companies.
With news expected next week, 79 cents for DSNY shares is a real Black Friday shopping deal.
I snagged 1,500 shares for 79 cents.
My trade hasn't yet shown up yet anywhere.
Correction - Now my trade appears 10+ minutes later.
I found a presentation on why PBPK works.
This graphical presentation is 3 years old, published by Roche.
http://www.thehamner.org/docs/pbpk_09/Day4.Lecture3.Best%20practices.pdf
It may answer some questions for investors who want to know some of the scientific reasons for GastroPlus and PBPK.
I found a review of GastroPlus vs alternatives.
This is only available on a Chinese company website called antpedia.
You may have to translate it into English using a Google translate features.
The Chinese version:
http://www.antpedia.com/news/48/n-210248.html
The English version using Google Translators:
http://translate.google.com/translate?hl=en&sl=zh-CN&u=http://www.antpedia.com/news/48/n-210248.html&prev=/search%3Fq%3DGastroPlus%2BFDA%26start%3D50%26hl%3Den%26sa%3DN%26tbo%3Dd%26biw%3D1179%26bih%3D840&sa=X&ei=ZiSvUI62GemliQK714DoCg&ved=0CGMQ7gEwBzgy
It shows GastroPlus in two tables versus 4-5 other comparative options.
The product names are:
PKSim, SimCyp, ChloePK, Current Pfizer approach, and GastroPlus.
GastroPlus seems to be the Clear winner - ranked 1st by a big margin.
TransTech Systems demos Cyclops 6 in NY next week.
TTS has reserved booth 655 at the ISC EAST Conference.
The booth is shown on the map link on the 2nd column from the right - above booth 548.
http://www.mapyourshow.com/shows/index.cfm?SHOW_ID=iscs12&alt_entry=true&curr_pri=facility&curr_sec=OO
http://www.isceast.com/Whos-Exhibiting/My-Show-Planner/
Happy Thanksgiving to all VSUL investors.
They announced the Japan Patent in October.
While the date says Oct 30th, I think I looked a few days ago and this patent was still listed as a patent application. They might be waiting for next week due to the reporting quit period.
I have been watching for the June 2012 patent applications to appear. Those patent applications have not been published yet.
Has Destiny announced their new US Patent?
http://www.freepatentsonline.com/8300885.html
The patent was approved on October 30th, 2012.
It is another version of their Watermarking technology.
They filed for this patent in June 2011.
The kit may include Cyclops 6 with software.
2013 is January. I expect them to be shipping the developer's kit before February.
The SPP agreement officially ends about May 2013. However, that agreement will like be renewed or change into something better - like a supplier agreement.
I like this paragraph on Visualant's website.
'For acquisition, joint venture, and licensing opportunities, or to obtain a developer's kit to explore applications in your industry, please call ...'
They could sign a licensing agreement at any time although I do not expect an agreement before the developer's kit is ready in 2013.
The negative cash flow could disappear very fast with two major licensing deals.
TransTech Systems could be at the ISCEAST conference next week.
Maybe there will be news on the rescheduled conference soon.
Stock Prices are all relative. A lot of stocks are priced below last year prices due to the fiscal cliff concerns.
I decided to buy more today at 11 cents.
VSUL is in a much better position now than last year.
Thanks. Here's my new slogan in audio.
http://soundcli.ps/sound/smarter-than-average-bear
Highlights of SLP's Conference Call.
All the same trends are underway.
-New MembranePlus module will be released in 2013.
-customer inquiries are up due to training classes and malaria drug results.
-Pharma companies need to lower costs to stay competitive. Some consolidations in industry.
-SLP and SymCyp/Certera are competing; SLP in the lead with Accurate Predictions.
-New Training Course scheduled for February.
-Looking for malaria drug development partner/funds and small acquisition opportunities.
-No announcement on the next New Drug Development project.
-Dividend plan is stable for now.